SYMDEKO is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
Materials and resources for healthcare professionals:
F508del Homozygous Clinical Trial Overview Brochure
Review information about patients with CF who are homozygous for the F508del mutation.
Review information about efficacy, safety, DDIs, and dosing.
Review considerations for initiating SYMDEKO.
See all indicated mutations for SYMDEKO.
Materials for you to share with your patients:
SYMDEKO Safety Overview
Provide patients with information about SYMDEKO safety and side effects
Guide to Taking SYMDEKO Brochure
Provide patients with information about how to take SYMDEKO and the importance of taking it with fat-containing foods.
Help patients learn how SYMDEKO works, and see study details, results, and possible side effects.